SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Sichuan Kelun-Biotech Reports Phase III Overall Survival Benefit in TNBC

The company said sacituzumab tirumotecan showed a statistically significant overall-survival benefit versus physician’s choice chemotherapy in previously treated TNBC, with no new safety signals at 29.4 months.

6990

Related stories